- Search for Research Summaries, Reviews, and Reports
- EPC Project
Related Patient Decision Aid
Research Review - Final – Feb. 5, 2008
Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer
- Final Report (PDF) 947 kB
- Final Appendixes (PDF) 2.2 MB
- Web Version (NLM Site)
- Help with Viewers, Players, and Plug-ins
Archived: This report has been updated.
People using assistive technology may not be able to fully access information in these files. For additional assistance, please contact us.
This report summarizes evidence comparing the relative effectiveness and safety of treatment options for clinically localized prostate cancer. The report addresses the following questions: 1) What are the comparative risks, benefits, short- and long-term outcomes of therapies for clinically localized prostate cancer? 2) How do specific patient characteristics, e.g., age, race/ethnicity, presence or absence of comorbid illness, preferences (e.g., tradeoff of treatment-related adverse effects vs. potential for disease progression), affect the outcomes of these therapies, overall and differentially? 3) How do provider/hospital characteristics affect outcomes overall and differentially (e.g., geographic region and volume)? 4) How do tumor characteristics, e.g., Gleason score, tumor volume, screen vs. clinically detected tumors, affect the outcomes of these therapies, overall and differentially?